Cantor Fitzgerald Brokers Lift Earnings Estimates for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities researchers at Cantor Fitzgerald lifted their FY2021 earnings per share estimates for shares of BioCryst Pharmaceuticals in a report released on Tuesday, January 11th. Cantor Fitzgerald analyst B. Cheng now forecasts that the biotechnology company will post earnings of ($1.30) per share for the year, up from their previous forecast of ($1.31). Cantor Fitzgerald also issued estimates for BioCryst Pharmaceuticals’ FY2022 earnings at ($1.06) EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Tuesday, November 2nd. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.04). The company had revenue of $40.99 million for the quarter, compared to the consensus estimate of $37.75 million. During the same quarter in the prior year, the company earned ($0.26) EPS.

Other equities research analysts have also issued research reports about the stock. Oppenheimer initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, December 9th. They set an “outperform” rating and a $16.00 price objective on the stock. Barclays dropped their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, November 4th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, November 8th. Finally, Royal Bank of Canada dropped their target price on shares of BioCryst Pharmaceuticals from $16.00 to $14.00 and set a “sector perform” rating on the stock in a research note on Thursday, November 4th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $19.82.

Shares of NASDAQ BCRX opened at $15.48 on Thursday. BioCryst Pharmaceuticals has a 1 year low of $8.37 and a 1 year high of $18.48. The company’s 50-day moving average is $12.87 and its 200 day moving average is $14.51. The stock has a market capitalization of $2.77 billion, a P/E ratio of -12.19 and a beta of 2.49.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCRX. Two Sigma Advisers LP grew its stake in BioCryst Pharmaceuticals by 171.3% in the third quarter. Two Sigma Advisers LP now owns 1,921,012 shares of the biotechnology company’s stock worth $27,605,000 after purchasing an additional 1,212,900 shares in the last quarter. Fisher Asset Management LLC grew its stake in BioCryst Pharmaceuticals by 49.4% in the third quarter. Fisher Asset Management LLC now owns 3,005,622 shares of the biotechnology company’s stock worth $43,191,000 after purchasing an additional 994,391 shares in the last quarter. Renaissance Technologies LLC grew its stake in BioCryst Pharmaceuticals by 1,430.3% in the second quarter. Renaissance Technologies LLC now owns 1,032,480 shares of the biotechnology company’s stock worth $16,324,000 after purchasing an additional 965,010 shares in the last quarter. Federated Hermes Inc. boosted its position in BioCryst Pharmaceuticals by 2,898.2% during the 2nd quarter. Federated Hermes Inc. now owns 746,971 shares of the biotechnology company’s stock valued at $11,810,000 after acquiring an additional 722,057 shares in the last quarter. Finally, PFM Health Sciences LP bought a new stake in BioCryst Pharmaceuticals during the 2nd quarter valued at $11,208,000. 57.20% of the stock is currently owned by hedge funds and other institutional investors.

In other BioCryst Pharmaceuticals news, Director George B. Abercrombie sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 15th. The stock was sold at an average price of $12.27, for a total transaction of $61,350.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jon P. Stonehouse sold 184,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 11th. The shares were sold at an average price of $15.04, for a total value of $2,767,360.00. The disclosure for this sale can be found here. Insiders sold 219,100 shares of company stock worth $3,195,930 over the last 90 days. Company insiders own 4.80% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever.

Read More: Technical Analysis of Stocks, How Can It Help

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.